Dihidrotestosteron (DHT) (Endocrine Sciences)
Kod:9029|CPT:82642|LOINC:1848-1
| Kabi | Dihidrotestosteron |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Yuqori samarali suyuq xromatografiya va tandem mass-spektrometriya (HPLC-MS/MS)
- Ferment immunoanalizi (EIA)
Kutilayotgan natija topshirish vaqti
1–2 kun
Maxsus tayyorlik
- Infants younger than 1 year: avoid feeding for 30–40 minutes before the draw.
- Children 1–5 years: fast for 2–3 hours prior to collection.
- Age 5 years and older: fast for 8 hours; water is allowed.
- Refrain from physical exertion and emotional stress for 30 minutes before collection.
- Do not smoke during the 30 minutes preceding collection.
Qanday foydalanish
Dihidrotestosteron (DHT) (Endocrine Sciences) tahlili jinsiy differensiasiya/rivojlanish buzilishlarining differensial diagnostikasida yordam beradi. DHT testosteronga nisbatan asossiz ravishda past bo‘lganda 5α-reduktaza yetishmovchiligini aniqlashga va testosteron:DHT nisbatini talqin qilishga yordam beradi. Ushbu analiz benign prostata giperplaziyasini, erkaklar va ayollarda androgenetik alopetsiyani, erkaklarda birlamchi va ikkilamchi gipogonadizmni, past libido va erektil disfunktsiya bilan namoyon bo‘luvchi yoshga bog‘liq androgen yetishmovchiligini, androgenlarga rezistentlik (Morris) sindromini hamda ayollarda, shu jumladan giperandrogen dermopatiyani o‘z ichiga olgan, giperandrogenizmni baholashga hissa qo‘shadi. DHT tekshiruvi, shuningdek, benign prostata giperplaziyasi yoki androgenetik alopetsiyada 5α-reduktaza ingibitorlari bilan davolash samaradorligini kuzatishda qo‘llanadi.
Cheklovlar
Dihidrotestosteron (DHT) testosterondan 5α-reduktaza tomonidan hosil bo‘ladi. Erkaklarda qon aylanishidagi DHT ham moyak sekretsiyasini, ham, undan ko‘proq darajada, testosteronning periferik konversiyasini aks ettiradi; ayollarda esa buyrak usti bezlari ishlab chiqarishi ustun bo‘lib, tuxumdonlarning kichikroq hissasi ko‘pincha androstenedion orqali bo‘ladi. DHT testosteronga nisbatan qon aylanishida pastroq konsentratsiyalarda mavjud bo‘lsa-da, androgen retseptoriga yuqoriroq affinitet bilan bog‘lanadi va kuchliroq androgenik ta’sirni vositachilik qiladi. Nishon to‘qimalar tarkibiga soch follikulalari, tashqi jinsiy a’zolar va skelet mushaklari kiradi. Prostatada DHT hujayra proliferatsiyasini testosteronga qaraganda kuchliroq rag‘batlantiradi. Ortiqcha DHT, jumladan ekzogen testosteron terapiyasi davomida kuzatiladigan ko‘tarilishlar, prostataning kattalashishiga hissa qo‘shadi va 5α-reduktaza ingibitorlari bilan davolash vaqtida DHT konsentratsiyasi prostata o‘lchami bilan parallel o‘zgaradi. Testosteron sintezining kamayishi yoki 5α-reduktaza faolligining buzilishi natijasida DHT pasayishi o‘g‘il bolalarda gipovirilizatsiyaga olib keladi: yuz, qov va qo‘ltiq sochlarining siyrakligi, mikropenis, kichik moyaklar, tashqi jinsiy a’zolarning anomaliyalari va mushak massasining kamayishi; yosh o‘tishi bilan u erektil disfunktsiya va libido pasayishi bilan bog‘liq. Aksincha, DHT ortishi bosh terisidagi soch o‘sishini susaytiradi va har ikki jinsda alopetsiyaga sabab bo‘ladi; ayollarda hayz sikli buzilishi va bepushtlik bilan birga kechuvchi giperandrogen dermopatiya yuzaga kelishi mumkin. 5α-reduktaza izofermentlarini ikkita gen kodlaydi: 5-xromosomada SRD5A1 va 2-xromosomada SRD5A2. SRD5A2 ning patogen variantlari DHT-ga bog‘liq tashqi jinsiy a’zolarning maskulinizatsiyasi buzilishi tufayli 46,XY jinsiy rivojlanish buzilishini — psevdovaginal perineoskrotal gipospadiyani — keltirib chiqaradi.
| O'lchov birligi | ng/dL | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Lower urinary tract symptoms attributed to benign prostatic hyperplasia, Pattern hair loss (androgenetic alopecia) in men or women, Monitoring during therapy with 5-alpha-reductase inhibitors, Men with diminished libido and erectile dysfunction, Anorchia, testicular atrophy, cryptorchidism, micropenis, or absent pubic/axillary hair, Assessment of pubertal maturation in boys, Women with hirsutism, acne, seborrhea, or menstrual cycle irregularity |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- testosterone
Pasaygan daraja
- 5-alpha-reductase inhibitors
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.5 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Douglas G, Axelrad ME, Brandt ML, et al. Guidelines for Evaluating and Managing Children Born with Disorders of Sexual Development. Pediatr Ann. 2012 Apr;41(4):e1-e7. PubMed 22494213
Goodman NF, Cobin RH, Futterweit W, et al. Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome—Part 1. Endocr Pract. 2015 Nov;21(11):1291-1300. PubMed 26509855
Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006 Jul;91(7):554-563. PubMed 16624884
Ocal G. Current Concepts in Disorders of Sexual Development. J Clin Res Pediatr Endocrinol. 2011;3(3):105-114. PubMed 21911322
Bartsch G, et al. Dihydrotestosterone and the Concept of 5α-reductase Inhibition in Human Benign Prostatic Hyperplasia. Eur Urol. 2000;37:367–380.
Zamrazilová L, Sosvorová L, Herácek J, Sobotka V, Hampl R. The content of five sex steroids in human testis. Physiol Res. 2012 Jan 31.
Dean A, Smith LB, Macpherson S, Sharpe RM. The effect of dihydrotestosterone exposure during or prior to the masculinization programming window on reproductive development. Int J Androl. 2012 Jan 17. doi:10.1111/j.1365-2605.2011.01236.x.
Shelby MK, Crouch DJ, Black DL, Robert TA, Heltsley R. Screening indicators of dehydroepiandosterone, androstenedione, and dihydrotestosterone use: a literature review. Anal Toxicol. 2011 Nov;35(9):638-655.